Warfarin Initiation and Monitoring with Clotting Factors II, VII, and X

Annals of Pharmacotherapy

Volumn 38, Issue 2, 2004, Pages 251-256

  Trask, Ashley S ^a,b   Gosselin, Robert C ^a   Diaz, Jaime A ^a   Dager, William E ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Factor II; Factor VII; Factor X; Heparin induced thrombocytopenia; International normalized ratio; Lepirudin; Monitoring; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; HEPARIN; LEPIRUDIN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; VITAMIN K GROUP; WARFARIN;

ABDOMINAL PAIN; ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DRUG DOSE REDUCTION; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPONATREMIA; HYPOTENSION; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; PATIENT MONITORING; PRIORITY JOURNAL; STROKE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOSIS;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FACTOR VII; FACTOR X; FEMALE; HIRUDINS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PLATELET COUNT; PROTHROMBIN; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; WARFARIN;

EID: 1642499303     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D266     Document Type: Article

References (28)

1. Moll S, Ortel TL. Monitoring warfarin therapy inpatients with lupus anticoagulants. Ann Intern Med 1997;127:177-85.
2. Smythe MA, Warkentin TE, Stephens JL, Zakalik D, Mattsow JC. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune and heparin-induced thrombocytopenia. Am J Hematol 2002;71:50-2.
3. Levine JS, Branch W, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
4. Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia: clinical diagnosis and implications - a review. Arch Pathol Lab Med 2000;124:1657-66.
5. Walenga JM, Jeske WP, Messmore HL. Mechanism of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2001;10(suppl):S13-20.
6. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
7. Warkentin T. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis 2001;10(suppl):S35-45.
8. Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999;45:409-12.
9. Dager WE, White RH. Authors' reply: treatment of heparin-induced thrombocytopenia (letter). Ann Pharmacother 2002;36:1484. DOI 10. 1345/aph.IA204b.
10. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti -phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
11. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;75:721-4.
12. Amengual O, Atsumi T, Khamashata MA, Hughes G. The role of tissue factor pathway in the hypercoagulable state in patients with antiphospholipid syndrome. Thromb Haemost 1998;79:276-81.
13. Walenga JM, Michal K, Hoppensteadt D, Wood JJ, Robinson JA, Bick RL. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost 1999;5(suppl 1):S76-84.
14. Denis-Magdeline A, Flahault A, Verdy E. Sensitivity of sixteen aPTT reagents for the presence of lupus anticoagulants. Haemostasis 1995;25:98-105.
15. Adcock DM, Marlar RA. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant. Arch Pathol Lab Med 1992;116:837-40.
16. Brandt JT, Triplett DA, Musgrave K, Orr C. The sensitivity of different coagulation reagents to the presence of the lupus anticoagulants. Arch Pathol Lab Med 1987;111:120-4.
17. 2-glycoprotein I. Thromb Haemost 1999;81:929-34.
18. Robert A, Le Querrec A, Delahousse B, Caron C, Houbouyan L, Boutirere B, et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome - influence of the lupus anticoagulant on the international normalized ratio. Groupe Methodolgie en Hemostsae du Groupe d'Etudes sur l'Hemostasis et la Thrombose. Thromb Haemost 1998;80:99-103.
19. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001;86:83-91.
20. Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983;61:684-92.
21. Moll S, Ortel T. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-85.
22. Bijsterveld NR, Middeldorp S, Berends F, Buller HR. Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination. J Thromb Thrombolysis 2000;9:263-9.
23. Le DT, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relationship to other monitoring methods. Ann Intern Med 1994;120:552-8.
24. D'Angelo A, Valle PD, Crippa L, Fattorini A, Pattarini E, D'Angelo SV. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulation treatment. Haematologica 2002;87:1074-80.
25. Paul B, Oxley A, Bringham K, Cox T, Hamilton PJ. Factors II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol 1987;40:94-8.
26. Kumar S, Haigh JRM, Tate G, Bouthby M, Joanes DN, Davies JA, et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control monitored compliance. Br J Haematol 1990;74:82-5.
27. Lind SE, Callas PW, Golden EA, Joyner KA, Ortel TL. Plasma levels of factors II, VII, and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coag Fibrin 1997;8:48-53.
28. Wittkowski AK. Thrombosis. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 7th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:14-5.